A pilot study of CHOP plus alemtuzumab for the primary treatment of ALK-ve peripheral T cell lymphoma.

Trial Profile

A pilot study of CHOP plus alemtuzumab for the primary treatment of ALK-ve peripheral T cell lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHOP-Campath
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by UKCRN.
    • 04 May 2012 Planned end date changed from 30 Apr 2012 to 2 May 2012 as reported by UKCRN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top